System Medical Director - Edward Elmhurst Helathcare
Oncology
Dr. Alexander Hantel, MD
|
|
Give Review
Alexander Hantel is an expert in the field of Oncology. He graduated from University of Illinois College of Medicine at Chicago. University of Illinois College of Medicine at Chicago is ranked 49/85 in Research/PrimaryCare. He received awards:"West Suburban Living Magazine", "CMS Meaningful Use Stage 1 Certification", "Super Doctor" and "Top MD". Dr. Alexander Hantel is a published doctor and has 34 publications published. The lastest was: 'A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group study 8918.' Alexander Hantel is registered with Medicare and accepts Medicare payments.
Publications
- Aspirin and COX-2 inhibitor use in patients with stage III colon cancer.
- Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial.
- Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance.
- Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance).
- Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
- A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group study 8918.
- Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. A Southwest Oncology Group trial.
- Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.
- A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study.
- Phase II trial of piroxantrone in gastric carcinoma. A Southwest Oncology Group study.
- Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.
- A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.
- A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.
- Nifedipine and oncologic Raynaud phenomenon.
- Clinical and pharmacologic reappraisal of dichloromethotrexate.
- Listeriosis in the setting of malignant disease. Changing issues in an unusual infection.
- Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
- Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
- Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
- Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study.
- Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803.
- Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.
- A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
- Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.
- KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
- Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
- Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemi...
- Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
- Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
- Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
- Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
- Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.
- Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances.
Schools
University of Illinois Hospital
John Hopkins Hospital
Procedures Preformed
- Thoracentesis
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- West Suburban Living Magazine
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
- Top MD
Education
-
Johns Hopkins University -
University of Illinois College of Medicine at Chicago -
University of Illinois College of Medicine
Hospital
-
Edward Hospital -
Elmhurst Memorial Hospital
Drug Facts
| NPI NUMBER | 1083691349 | |
| NPPES Provider LastName | HANTEL | |
| NPPES Provider FirstName | ALEXANDER | |
| NPPES Provider ZIPCode | 605406766 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1710.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 181.0 | |
| Percent Opioid Claims | 10.58 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083691349 |
| Last Name Of The Provider | HANTEL |
| First Name Of The Provider | ALEXANDER |
| View All |
Similar Doctors
|
Dr. Rafael A. Perez-Guerra, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph J. Kash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saadia Yunus, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hassan Pervez, MD
This Doctor is OpenDoctor Recommended.
|